Christopher Melani retweetledi
Do you have an aggressive B-cell #Lymphoma that has either come back or persisted after initial therapy? If so, you may be eligible to participate in #ClinicalTrial EA4231. More info here: bit.ly/EA4231 #lymsm
English
Christopher Melani
390 posts
Christopher Melani
@MelanicjMD
Clinician and researcher specializing in lymphoma. Tweets are my own.
Baltimore, MD Katılım Haziran 2017
234 Takip Edilen634 Takipçiler
Open to enrollment or soon to open in nearly 150 sites across the USA as of last month! Please consider referring patients or opening at your own site to access this promising treatment for your aggressive #lymphoma patients. @theNCI @lymphoma
ECOG-ACRIN Cancer Research Group@eaonc
Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: bit.ly/EA4231 cc: @MelanicjMD, @theNCI, @UVACancerCenter
English
Currently enrolling patients with R/R CD10-negative DLBCL and HGBCL-DH-BCL2 across multiple EA sites in the USA including @theNCI. Please consider this encouraging study for your patients that may benefit!
ECOG-ACRIN Cancer Research Group@eaonc
Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: bit.ly/EA4231 cc: @MelanicjMD, @theNCI, @UVACancerCenter
English
Christopher Melani retweetledi
Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…
English
Christopher Melani retweetledi
Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: bit.ly/EA4231 cc: @MelanicjMD, @theNCI, @UVACancerCenter
English
Christopher Melani retweetledi
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Co-authored by @AshAlizadeh, @RoschewskiMD, @DrJasonWestin, @max_diehn, @Rcl14L
Read the full article. brnw.ch/21wV02q
#lymsm
English
Christopher Melani retweetledi
Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…
Read this paper which shows that ctDNA MRD by PhasED-Seq is the most precise way to define a remission after therapy for LBCL.
English
Excited to validate our single-center @theNCI findings in this multi-center phase II study in additional patients with #lymphoma. Please consider referring patients or opening at your site if interested.
ECOG-ACRIN Cancer Research Group@eaonc
Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: bit.ly/EA4231 cc: @MelanicjMD, @theNCI, @UVACancerCenter
English
Christopher Melani retweetledi
Patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment may be eligible to participate in #ClinicalTrial EA4231. Learn more here: bit.ly/EA4231 cc: @MelanicjMD, @theNCI, @UVACancerCenter
English
Christopher Melani retweetledi
#ClinicalTrial EA4231, led by @MelanicjMD of @theNCI, is testing the effectiveness of a combination #TargetedTherapy for patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment. For more info: bit.ly/EA4231 cc: @LLSusa, @lymphomahub
English
Such a thrill to watch @Hememachine receive the Henry Kaplan award at #ICML2025! Well deserved indeed and an honor to be able to review our #lymphoma cases weekly with her under the microscope @theNCI 👏🏻👏🏻👏🏻
English
Christopher Melani retweetledi
Results from our Phase III ECHO trial of acalabrutinib + BR vs placebo + BR in untreated MCL patients ≥ 65-y.o. showed PFS was substantially improved in the acalabrutinib arm (66.4 vs 49.6 mo., p = 0.016). Toxicity in both arms was manageable. tinyurl.com/ECHO-ABR
English
English
Christopher Melani retweetledi
Helpful review on ctDNA in lymphoma from @RoschewskiMD et al just out in @JAMAOnc
@dgermain21 @AshAlizadeh #lymsm #lymphoma @hjcherng @JAMA_current @JAMANetwork
JAMA Oncology@JAMAOnc
This narrative review explores how the identification of measurable residual disease through methods of detecting circulating tumor DNA contributes to outcomes for B-cell lymphomas. ja.ma/4jQUHju
English
Christopher Melani retweetledi
Great news! I predict the tip of the iceberg for these tests.
foresight-dx.com/press_releases…
English
Christopher Melani retweetledi
@MelanicjMD MRD dynamics attached. 13% progressed after EOT with MRD lead time of 2.3 months. #ASH24 #lymsm
English
Christopher Melani retweetledi
Time-limited VIPOR MCL @MelanicjMD #ASH24
- 37 pts, 20 untreated, 34% whole cohort TP53mut
- significant hypokalemia (27% G3!), diarrhea, rash
- CR: 94% R/R, 100% untreated (!!!), 92% TP53mut
- 2-yr TTP 95% 1L, 92% R/R
Great data, especially TP53mut-enriched R/R cohort. #lymsm
English
Beautiful sunrise to kick off day 1 of #ASH2024. Looking forward to a very educational and productive meeting!
English
Christopher Melani retweetledi
Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity | PNAS pnas.org/doi/10.1073/pn…
Read the background story of how the VIPOR drugs were discovered to have synergy in LBCL.
English